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ABSTRACT
The specific down-regulation of gene expression in
cells is a powerful method for elucidating a gene’s
function. A common method for suppressing gene
expression is the elimination of mRNA by RNAi or
antisense. Alternatively, oligonucleotide-derived
aptamers have been used as protein-directed agents
for the specific knock-down of both intracellular and
extracellular protein activity. Protein-directed meth-
ods offer the advantage of more closely mimicking
small molecule therapeutics’ mechanism of activity.
Furthermore, protein-directed methods may syner-
gize with RNA-directed methods since the two
methods attack gene expression at different levels.
Here we have knocked down a well-characterized
intracellular protein’s activity, NFkB, by expressing
either aptamers or small interfering RNAs (siRNAs).
Both methods can diminish NFkB’s activity to similar
levels (from 29 to 64%). Interestingly, expression of
both aptamers and siRNAs simultaneously, sup-
pressed NFkB activity better than either method
alone (up to 90%). These results demonstrate that
the expression of intracellular aptamers is a viable
alternative to siRNA knock-down. Furthermore, for
the first time, we show that the use of aptamers and
siRNA together can be the most effective way to
achieve maximal knock-down of protein activity.
INTRODUCTION
Genome-wide sequencing projects have lead tothe uncovering
of thousands of new genes of unknown function. However, the
role of well-studied genes in complex multi-gene dependent
processes, such as disease pathology, remains hidden. Thus,
there is a strong need for methods for the elucidation of gene
function, particularly in relation to disease progression. The
most effective methods for this purpose are those that suppress
gene activity (1,2). Various methods target gene expression at
the DNA, mRNA or protein level (2). Once a gene’s activity is
speciﬁcally suppressed the effects can be assessed in either
mechanistic or disease models.
RNAi has become a widely used tool for the suppression of
gene activity in invertebrates, plants, and, with the advent of
small interfering RNA (siRNA) techniques, in mammalian
cells (3–5). siRNAs can be introduced via direct transfection
or by expression from various plasmids either transiently or
stably (6–8). The siRNA molecules bind to a protein complex,
called the RNA-induced silencing complex. This complex
contains a helicase activity that unwinds the two strands of
RNA molecules, allowing the antisense strand to bind to the
targeted RNA molecule (9) and an endonuclease activity that
hydrolyzes the target RNA at the site where the antisense
strand is bound.
Although a powerful method, there are limits to siRNA
techniques. Firstly, siRNAs don’t always promote complete
degradation of mRNA (10,11). If even a small amount of
mRNA survives it may be able to produce sufﬁcient amounts
of protein for signiﬁcant activity. Secondly, recent studies
indicate that siRNAs can have adverse effects by activating
sensors in the interferon response pathway (12,13) or other
non-speciﬁc genes (14). Finally, siRNA (as well as antisense
or gene knock-out strategies) may completely or severely
deplete targeted protein levels. Since many proteins exist in
multi-protein complexes that may be involved in multiple
functional pathways, deleting the protein will likely have
pleiotropic effects not speciﬁc to the relevant pathway.
Recently, nucleic acid-derived aptamers have been used to
regulate intracellular protein activity (2,15). Aptamer
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doi:10.1093/nar/gnj028‘decoys’, short RNAs containing the RNA-binding site for
HIV-1 RNA-binding proteins, such as Rev and Tat, have
been developed that inhibit HIV-1 replication when over-
expressed (16,17). Aptamers speciﬁc to non-RNA-binding
proteins, as well as RNA-binding proteins, can be generated
byaninvitro process knownassystematic evolutionofligands
by exponential enrichment (SELEX). These non-decoy apta-
mers can bind with high speciﬁcity and afﬁnity (2,18) and can
knock-out intracellular protein activity (19). For instance,
aptamers that recognize the cytoplasmic domain of the b2-
integrin, leukocyte function-associated molecule-1 (LFA-1)
have been isolated (19,20). LFA-1 mediates the adhesion of
leukocytes in immune responses by binding to intercellular
adhesion molecules (21). Intracellular expression of anti-LFA-
1 aptamers inhibits LFA-1 activity, as measured by a decrease
in cell adhesion (19). Mayer et al. (22) have extended these
observations by blocking the intracellular function of
cytohesin-1, a guanine-nucleotide-exchange factor that is
thought to regulate the adhesion of LFA-1 to ICAM-1, with
an anti-cytohesin 1 aptamer. Moreover, aptamer-based cyto-
hesin-1 inhibition results in a decrease in cell adhesion and
cytoskeletal rearrangement.
In this study, we have used an anti-NFkB aptamer, a-p50
(23), that has been shown previously to inhibit the DNA-
binding activity the p50 subunit of the NFkB transcription
factor in yeast (23,24), to, for the ﬁrst time, knock-down
NFkB activity in mammalian cells. Furthermore, we have
knocked down NFkB activity with siRNA. We ﬁnd that
both aptamers and siRNAs when used alone knock-down
the activity of NFkB to a similar extent and interestingly,
when used in combination the two methods work better
than either method alone, leading to essentially complete
(90%) knock-down of NFkB activity.
MATERIALS AND METHODS
Plasmids
U6/TAR-a-p50 contains a U6 promoter followed by the
TAR-a-p50 sequence. It was made by inserting the a-p50-
TARsequence,GGGTCTCTCTGGTTAGCATCCTGAAAC-
TGTTTTAAGGTTGGCCGATGTAGCTAGGGAACCCACT
(ﬂanked by XhoI/BamHI sites and generated by PCR), into the
XhoI/BamHI restriction sites of the plasmid MYHIV (kindly
provided by Nouria Hernandez). The HIV-1 promoter
sequence was then replaced by the pol III U6 promoter by
inserting a PCR-generated fragment into EcoRI/XhoI linear-
ized plasmid.
pAV7SL-a-p50 was made by inserting a PCR-generated
fragment consisting of anti-NFkB aptamer a-p50 (23)
(Figure 1) into the SalI–XbaI sites of pAV7SL (kindly pro-
vided by D. Engelke).
pSilencer-2.0-U6-siRNA2 was made by inserting the frag-
ment encoding siRNA2: TATTAGAGCAACCTAAACA into
the XbaI/BamHI sites of the vector pSilencer (Ambion).
Design of short interfering RNA (siRNA)
siRNA targeting NFkB p50 was designed according to Tus-
chl’s method found online http://www.rockefeller.edu/
labheads/tuschl/sirna.html. The sequence and its complement
is BLAST searched against the human genome to ensure that
only NFkB p50 was targeted. Six sequences were designed
siRNA1, TGGCAGAAGATGATCCATATT; siRNA2,
TATTAGAGCAACCTAAACATT; siRNA3, AGGTTATTG-
TTCAGTTGGTTT; siRNA4, GTACAGGTCCAGGGTATA-
GTT; siRNA5, AGCCCTAAAATTCACTGCGTT; siRNA6,
TATTTAATCCAGAAGTATTTT.
The sequence that showed the greatest ability to reduce
protein levels by western blot after in vitro transcription
and transfection (see below) was sequence 2. Sequence 2
typically knocked down protein levels from 55 to 65%
(Figure 4) while both sequence 4 and sequence 6 typically
knocked down protein levels from 40 to 50% (data not shown).
Sequences 1, 3 and 5 showed activity now.
Western blot analysis of cells transfected with
in vitro transcribed siRNAs
HeLa cells were cultivated in DMEM supplemented with 10%
fetal bovine serum (FBS) in 12-well culture dishes at a density
of 100 000 cells/well 24 h before transfection. siRNAs were
in vitro transcribed using Ambion’s (Austin, TX) Silencer
siRNA Construction kit. siRNA was transfected into HeLa
cells using siPORT Lipid (Ambion, Austin, TX) with a
siRNA concentration of 40 and 50 nM. ssRNA control was
simplythetopstrandonlyoftheindicatedsequence.After48h
incubation in a 37 C incubator, the HeLa cells were stimulated
with human TNFa at a concentration of 10 ng/ml for 4 h. The
cells were extracted over ice in extraction buffer (10 mM Tris,
pH 7.5, 100 mM NaCl, 0.125% NP-40, 0.875% Brij 97,
1.5 mM Na-Vanadate, 1 mini-EDTA free protease inhibitor
tablet Roche). Total protein concentration levels were determ-
ined using a BCA Protein Assay kit (Pierce). Total protein
(2 mg) was loaded into a 15-well Invitrogen NuPAGE Novex
10% Bis–Tris gel (Carlsbad, CA) and run in 1· MES Buffer
(20· MES: 1 M MES, 1 M Tris Base, 69.3 mM SDS, 20.5 mM
EDTA, pH 7.3) for 35 min at a constant 200 V. Transfer of 1 h
at a constant 30 V onto nitrocellulose ﬁlm using 1· NuPAGE
Transfer Buffer (20· Transfer Buffer: 500 mM Bicine,
500 mM Bis–Tris, 20.5 mM EDTA, 1 mM Chlorobutanol,
pH 7.2).
Western blots used antibodies to NFkB-p50 (Upstate
Cell Signaling Solutions, Charlottesville, VA) and TFIII-B
(kindly provided by N. Hernandez) at a dilution of 1:5000.
The TFIII-B antibody serves as an internal control to normal-
ize for variations in protein loading. The nitrocellulose ﬁlm
was incubated overnight in primary antibody followed by 1 h
secondary anti-rabbit antibody incubation. Imaging is done
with ECL western blot kit (Amersham, Piscataway, NJ) and
the ﬂuorescence was read at on the STORM machine accord-
ing to Amersham protocol.
Western blot analysis of cells transfected with
siRNA-expressing constructs
HEK293 cells were plated in 12-well plates at 100 000 cells/
well in 1 ml of DMEM supplemented with 10% FBS and P/S.
siRNA plasmid (450 ng) and 50 ng of GFP plasmid were
transfected by Fugene 6. TNFa (Calbiochem, San Diego,
CA) was added at 10 ng/ml concentration 48 h later for
6 h. Cell extracts were generated by lysis in extraction buffer
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Brij 97, 1.5 mM Na-Vanadate and 2 mM EDTA protease free
inhibitor). Protein (7.5 mg) (as determined by Bradford assay)
of each sample was run on a NuPAGE 10% Bis–Tris gel using
the invitrogen gel running system. Western blot analysis was
performed as above.
Electrophoretic mobility shift assay (EMSA)
A DNA probe containing the binding site for NFkB was con-
structedusingthe followingprimers: 50-GCC ATGGGG GGA
TCC CCG AAG TCC-30 and the reverse primer 50-GGA CTT
CGG GGA TCC CCC CAT GGC-30. PAGE puriﬁed primers
A
B
Figure 1. Diagram of theoretical transcript generated from aptamer expression constructs. (A) Transcript generated from 7SL-a-p50. 7SL sequences are in black,
aptamersequenceinredandterminatorsequenceinblue.(B)TheHIV-1TARtranscript(left),a59ntstablestemandloopstructure.TheDNAencodingthestemalso
encodesthebipartiteISTelement[incyan(25)].ThesequencemostimportantforTatbindingisshowninblack.TomakeTAR-a-p50(right)theTatbindingsitewas
replaced with the similarly shaped p50 aptamer (in red).
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IL). Single-stranded oligonucleotides were annealed and end-
labeled using Gibco (Carlsbad, CA) polynucleotide kinase and
50 mCi gamma p32 ATP. Label was ethanol precipitated and
resuspended in TE buffer.
Lysates were prepared from HeLa or 293 cells grown to 60–
90% conﬂuency in 6-well dishes. Cells were grown in DMEM
orRPMIplus10%fetalcalfserum. Theywerewashedtwicein
phosphate-buffered saline (PBS) and then stimulated with
TNFa in RPMI for 10 min at 37 C. After being washed
once with PBS, lysates were made using 200 mL extraction
buffer (as per western blot extraction buffer, described above).
Lysates were cleared by centrifugation and stored at  80 C
before use.
For the gel-shift, 1 ml of extract was incubated with 2 mlo f
aptamer to which 1 ml of polyDIDC, 1 ml of probe and 5 mlo f
binding buffer (20 mM Tris, pH 8, 200 mM KCl, 10 mM
MgCl2, 20% glycerol, 0.1% NP40, 1 mM DTT, 0.4 mg/ml
BSA) was added. Reactions occurred for 15 min at room
temperature. Samples were loaded onto 6% DNA retardation
gels (Invitrogen) and run in 0.5· TBE at 150 V for 1.5 h at
room temperature. Dried gels were placed on phosphoimager
plates and radioactive bands were visualized by analysis with
the Storm 860 (Molecular Dynamics, Sunnyvale, CA).
NFkB luciferase assays
HEK293 cells were cultivated in DMEM supplemented in
10% FBS in 96-well white plates at a density of 10 000
cells/well 24 h before transfection. NFkB TA Luciferase plas-
mid (5 ng) (Clontech) along with 80 ng of siRNA expression
plasmid and 7SL expression plasmid were introduced into
HEK293 cells using fuGENE 6 (Roche). Cells were stimulated
with human TNFa at a concentration of 10 ng/ml for 5 h at
37 C, 24 h later. Luminescence was measured using the
Steady-Glo kit (Promega) and a TopCount Luminometer. In
the combination experiments, 35 ng of the pAV7SL-derived
plasmid, 55 ng of the pSilencer-derived plasmid and 5 ng of
NFkB TA Luciferase plasmid were used per well.
RESULTS
Knock-down of in vivo NFkB activity with
RNA aptamers
Using in vitro selection methods, Cassiday and Maher (24)
identiﬁed a 31 nt RNA aptamer that binds to the p50 subunit of
NFkB with high afﬁnity. Furthermore, they showed that this
aptamer can inhibit the p50/p65 heterodimer protein from
binding to its cognate DNA-binding site in vitro and in a
yeast three-hybrid assay. To knock-down intracellular
NFkB activity we expressed this aptamer in mammalian
cells with various expression constructs. To deliver a-p50
we used the vector pAV-7SL which places the aptamer within
the natural cytoplasmic RNA 7SL and drives expression with
the 7SL promoter (Figure 1A). We also developed a novel
expression vector. The vector U6-TAR expresses the HIV-1
TAR construct to high levels driven by the pol III U6
promoter. This vector also contains the HIV-1 IST element
which has been shown to dramatically increase production of
short transcripts from variety of promoters including the U6
promoter (25,26). We replaced the dispensable top of the TAR
which contains a natural aptamer that binds the HIV-1 Tat
protein with a-p50 (Figure 1B). EMSA studies using aptamers
produced from these plasmids in vitro show that a-p50 is
capable of inhibiting p50 binding within the context of 7SL
or TAR (Figure 2A and B, respectively) and the 7SL or TAR
alone cannot. RT–PCR of extracts from cells transfected with
these vectors with probes speciﬁc for the predicted RNA apta-
mers verify that both vectors are capable of expressing the
aptamers (data not shown).
To determine if expression of these aptamers can inhibit
NFkB function in mammalian cells, either the parent con-
structs (7SL or U6-TAR) or the respective a-p50 aptamer
expression vectors were co-transfected into 293 cells with a
NFkB dependent luciferase reporter construct. Transfected
cells were treated with TNFa to enhance NFkB activity
and luciferase levels were measured 6 h later. The results
in Figure 3A show that in untreated cells co-transfected
with 50 ng of 7SL-a-p50 NFkB levels are reduced 39% com-
pared with control plasmids and this reduction increases to
51% upon TNFa stimulation. Similarly, although less dramat-
ically, in unstimulated cells co-transfected with 50 ng of TAR-
a-p50 there is a small but reproducible down-regulation of
NFkB activity (11%) compared with cells transfected with
the same amount of control plasmid (Figure 3B). Stimulation
of NFkB activity by TNF-a treatment increases
Figure 2. a-p50 retains NFkB-binding activity within the context of 7SL and
TAR RNA vehicles. Lysates from TNFa stimulated 293 (A) or HeLa (B) cells
wereincubatedwithtitrationsofinvitrotranscribeda-p50orcontrolaptamerin
thepresenceofradiolabeledNFkBDNAprobe.Sampleswererunon6%DNA
retardation gels and then visualized after being exposed to phosphoimager
plates. Lane 1, no TNF A. Lanes 2–10, with TNFa at 10 ng/ml. Lane 2, no
aptamer. Lane 3, 25 mg/ml 7SL a-p50. Lane 4, 12.5 mg/ml 7SL a-p50. Lane 5,
5mg/ml7SLa-p50.Lane6,2.5mg/ml7SLa-p50.Lane7,25mg/ml7SL.Lane8,
12.5 mg/ml 7SL. Lane 9, 5 mg/ml 7SL. Lane 10, 2.5 mg/ml 7SL. Shown experi-
ment is representative of multiple experiments. (B) Lanes 2–10, with TNFa at
30ng/ml.Lane2,TNFaalone.Lane3,90mg/mlTAR-a-p50.Lane4,45mg/ml
TAR-a-p50.Lane 5, 30 mg/mlTAR-a-p50.Lane6, 10 mg/mlTAR-a-p50. Lane
7, 90 mg/ml TAR transcript. Lane 8, 45 mg/ml TAR. Lane 9, 30 mg/ml TAR.
Lane 10, 10 mg/ml TAR. Shown experiment is representative of multiple
experiments.
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plasmid (up to 80 ng) did not increase inhibition although
transfecting smaller amounts showed dose responsive
decreases in inhibition (data not shown).
To determine if siRNA could also inhibit NFkB activity, a
series of siRNAs were designed by the method of Tuschl (see
Materials and Methods), transcribed in vitro, and transfected
into 293 cells. The amount of NFkB protein and a control were
assayed by western blot and gel-shift analysis 48 h later. Of the
sequences tested, siRNA2 yielded the best results, reducing
protein levels by 61% (Figure 4).
Next we wanted to compare siRNA’s and aptamer’s ability
to reduce NFkB activity in our NFkB dependent luciferase
assay. To more easily compare the two methods we delivered
siRNA2into the cellbyexpression from aplasmid. Expression
of siRNA2 resulted in signiﬁcant reductions in protein levels
by western blot (Figure 4B). Expression of siRNA2 also sig-
niﬁcantly reduced NF-kB activity (63%, Figure 4C).
Since aptamers and siRNA work at different levels of the
gene expression pathway, we theorized that combining the two
methods might lead to stronger inhibition. We tested this by
transfecting different combinations of the siRNA-expressing
plasmid and aptamer expressing plasmids. As shown in
Figure 5, transfection of siRNA2 along with control 7SL plas-
mid results in 64% reduction in NFkB activity compared with
the control.Furthermore, transfection of 7SL-a-p50 alongwith
siRNA control results in 62% repression. Transfection of both
7SL-a-p50 and siRNA2, however, leads to 90% reduction of
NFkB activity. Thus, the most effective way to knock-down
NF-kB activity using the two methods is to use them in
combination. Interestingly, the TAR-a-p50 also enhances
siRNA2’s ability to inhibit NFkB activity (Figure 5B).
Predictably, the effect is smaller, demonstrating a type of
dose dependence, in that the weaker construct enhances to
a weaker extent.
DISCUSSION
We have signiﬁcantly down-regulated activity of the intracel-
lular protein, NFkB, in mammalian cells by expressing RNA
Figure 4. siRNAreducesNFkBproteinlevelsandactivity.(A)Westernblotof
extract from cells mock transfected (Zero A and B), with 50 nM in vitro
transcribed single-strand control RNA using the top strand only (ssRNA Con-
trol A and B) or 50 nM siRNA sequence number2 (siRNA2 A and B). A and B
refer to extracts from identically treated cells. The blot was simultaneously
treated with antibody to the p50 subunit of NFkB and the TFIIB transcription
factor (that should not be affected by siRNA treatment). Shown experiment is
representative of three experiments. (B) Bar graph of normalized results of
western blot of cells transfected with control p-Silencer-2.0 (Ambion) plasmid
(CONTROL) or pSilencer-2.0-U6-siRNA2 (SEQ 2). Shown experiment is
representative of three experiments. (C) Bar graph of results of NFkB-depen-
dent luciferase assay of cells transfected with NF-kB-dependent reporter plas-
midandp-Silencer-2.0 (siRNACON)orpSilencer-2.0-U6-siRNA2(siRNA2).
Shown experiment is representative of three experiments.
Figure 3. TNFatreated7SL-a-p50andTAR-a-p50transfectantsshowreduced
NFkB-luciferase activity compared with vehicle controls. The 293 cells were
co-transfected with NFkB-luciferase reporter and 7SL or 7SL-a-p50 (A)o r
TAR or TAR-a-p50 (B). Transfectants were treated with TNFa at 20 ng/ml
(plus)ormediumalone(minus).Substrateandlysissolutionwasaddedtocells
andfluorescencewasmeasuredandreportedasrelativeluciferaseunits(RLU).
Shown experiment is representative of multiple experiments. Error bars gen-
erated by Microsoft Excel.
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vectors. pAV7SL uses sequences derived from the natural 7SL
siRNA to stabilize the transcript and direct it to the cytoplasm.
It has been used previously to generate large numbers of small
RNAs (D. Engelke, personal communication) but this is the
ﬁrst time it has been used to express an inhibitory aptamer.
The second construct, U6/TAR, is novel and based on the
construct U6-HIV/LTR (25) that expresses the natural, pre-
dominantly nuclear (27) HIV-1 TAR aptamer from the U6
promoter. This construct offers several advantages over
other published nuclear-directing constructs. Firstly, the
RNA vehicle generated is simple compared with tRNA-
based constructs (28). Secondly, the TAR has been reported
to be very stable, with a half-life of 2–3 h in vivo (29). Finally,
the DNA encoding the bottom third of the TAR contains an
IST (inducer of short transcripts) element. The IST element
has been shown to dramatically increase the amount of con-
stitutively produced short transcripts from a variety of pro-
moters including the U6 promoter (25). Thus, this plasmid
would be expected to produce signiﬁcantly more aptamer
than other vectors containing snRNA promoters (U6 or
U1).7SL-a-p50ismoreeffectivethan TAR-a-p50 atinhibiting
NFkB activity (29% versus 51%). This could be due to dif-
ferences in stability/folding of the RNA transcripts or to pos-
sible differences in the distribution of the different transcripts.
It is also possible that the difference in the ﬁrst 2 bp of the stem
of the aptamer introduced during the making of the constructs
affected binding in vivo although we believe this unlikely as
two constructs inhibited NFkB binding similarly in vitro.
There are theoretical and practical reasons for combining
siRNA and aptamers. They are both RNA molecules and can
be introduced in similar ways (i.e. expressed from plasmids or
in vitro transcribed and directly transfected). They work by
inhibiting different levels of the protein expression pathway
thus they are unlikely to interfere with each other and more
likely to synergize. Here we demonstrated, for the ﬁrst time,
that the simultaneous expression of siRNA and RNA aptamers
in cells inhibits a protein’s expression better than either
method alone. This technique will be useful in situations
where a near complete knock-out is desired and neither tech-
nique is capable of doing the job alone.
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